Biomea Fusion, Inc.

NASDAQ:BMEA

7.85 (USD) • At close September 13, 2024
Bedrijfsnaam Biomea Fusion, Inc.
Symbool BMEA
Munteenheid USD
Prijs 7.85
Beurswaarde 284,250,070
Dividendpercentage 0%
52-weken bereik 3.61 - 22.74
Industrie Biotechnology
Sector Healthcare
CEO Mr. Thomas Andrew Butler
Website https://biomeafusion.com

An error occurred while fetching data.

Over Biomea Fusion, Inc.

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in

Vergelijkbare Aandelen

Longeveron Inc. logo

Longeveron Inc.

LGVN

2.08 USD

Chimerix, Inc. logo

Chimerix, Inc.

CMRX

0.855 USD

Harvard Bioscience, Inc. logo

Harvard Bioscience, Inc.

HBIO

2.88 USD

OptiNose, Inc. logo

OptiNose, Inc.

OPTN

0.905 USD

Inozyme Pharma, Inc. logo

Inozyme Pharma, Inc.

INZY

6 USD

High Tide Inc. logo

High Tide Inc.

HITI

2.23 USD

Omeros Corporation logo

Omeros Corporation

OMER

3.94 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)